anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in the United States. It is approved for the treatment of Mycobacterium leprae (leprosy) infections. Clofazimine has been used for many years off-label against other Mycobacterium, including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent infection in older Americans. The U.S. Food and Drug Administration currently oversees clofazimine use to treat MAC lung disease through a special investigational drug access program. However, to date, there is little understanding of the benefits and risks of clofazimine when used to treat MAC lung disease. Accordingly, the investigators have developed a randomized, placebo-controlled clinical trial to assess the clinical efficacy and safety of clofazimine. To be eligible, participants must have MAC lung disease, positive sputum cultures for MAC, and not currently taking antibiotics for MAC. Eligible participants (102 total enrolled) will be randomly given either clofazimine or placebo for 6 months, and followed closely by their treating physician. The percentage of participants who become culture negative in each group will be compared, as it is suspected that participants treated with clofazimine will be more likely to become culture negative. The safety of clofazimine will be measured as well as other potential benefits of the therapy including changes in lung function and quality of life.
The functional status of the subscapularis following total shoulder arthroplasty has not been well documented. There is evidence of loss of subscapularis function shown through physical exam in up to 2/3 of patients following total shoulder arthroplasty. \[1\] Multiple techniques for subscapularis repair have been demonstrated with varying degrees of post operative function, ranging from 11-66% abnormal function on physical exam. \[1-3\] The belly compression test and the lift off test, which are the main physical exam tests used for evaluation following surgery, are of questionable reliability as indicators of the functionality of the subscapularis. \[4,5\] Through comparing ultrasound evidence of an intact subscapularis to physical exam findings it has been recognized that the belly compression test has low sensitivity and specificity for subscapularis integrity. \[5\] Internal rotation is often limited in many postoperative total shoulder patients, which could lead to false positive results. This questions the validity of the outcomes of the studies in which the standard of testing function was through exam.

Ultrasound is a reliable exam for illustration of structural damage to the subscapularis tendon but additional testing is needed to evaluate the function of the structurally intact subscapularis. \[5,6\] Irreparable changes in the muscle function or nerve denervation could also result in false positive belly compression and lift off tests. The ability to accurately determine the functionality of the subscapularis following total shoulder replacement is imperative to clinic management. Although studies have shown functional abnormalities through physical exam, none have documented the functional status of the subscapularis using objective means such as EMG.
BACKGROUND: Patients having COPD share some factors, e.g., chronic hypoxemia, anemia of chronic disease and nicotine use, which are also the risk factors for RLS hence predispose them to experience RLS in higher then general population. There are limited studies with methodological constraints evaluating the prevalence and/or correlates of RLS among patients with COPD.
METHODS: Consecutive adult patients of either gender, having stable COPD as per GOLD guidelines 2021, were assessed for RLS using IRLSSG (2014) criteria (excluding RLS mimics) and the severity of RLS was determined in participants having RLS. Phenomenology of RLS, past medical history and laboratory parameters were gathered. Insomnia and depression were assessed using the insomnia severity index and PHQ-9, respectively.
RESULTS: Participants' (N = 210) mean age was 63.02 ± 8.19 years, and 83.8% of subjects were men. 12.9% of participants were found to have RLS. Among those having RLS, nearly half (51.9%) had moderate symptoms, and 18.5% experienced severe symptoms. RLS was more prevalent among younger, females, those having severe COPD, participants having exacerbation of COPD in the previous year, lower post-bronchodilator FEV1, higher dyspnea and COPD assessment test score. Multivariate analysis showed that younger age, female gender, lower post-bronchodilator FEV1, lower FEV1/FVC ratio and higher serum creatinine increased the odds of having RLS. Depressive symptoms were more frequent in participants having RLS.
CONCLUSIONS: The present study found that the prevalence of RLS among patients with stable COPD was higher than the general population. Female gender, younger age, higher airflow limitation and higher serum creatinine (though in the physiological range) increase the odds of having RLS. Stable patients with COPD having these characteristics must be screened for RLS.
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. 

Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. 

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. 

Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:
Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
Angina pectoris has not been reported upon labetalol hydrochloride discontinuation. However, hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abruptdiscontinuation of such therapy. When discontinuing chronically administered labetalol hydrochloride, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, therapy with labetalol hydrochloride should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue therapy with labetalol hydrochloride abruptly in patients being treated for hypertension. 

NonallergicBronchospasm(e.g.,ChronicBronchitis andEmphysema)Patients withbronchospasticdiseaseshould,ingeneral,notreceivebeta-blockers.Labetalol hydrochloride may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. It is prudent, if labetalol hydrochloride is used, to use the smallest effective dose, so that inhibition of endogenous or exogenous beta-agonists is minimized.
After 6 weeks, participants undergo the midterm assessments. Then, participants will start with the 8-week Strolll AR intervention (i.e., 2 weeks of practice supervised in the clinic and 6 weeks of training independently at home) and will receive a final assessment hereafter.
A woman in her 30s presents to the Differences in Sexual Development Programme at a tertiary care academic medical centre with vaginal stenosis and scarring. Her medical history is significant for virilisation in utero due to a maternal luteoma of pregnancy. Laboratory investigations at the time of birth showed elevated androgens in both mother and daughter. During infancy, she underwent clitoroplasty and vaginoplasty for correction of posterior vaginal fusion. She represented as an adult with vaginal stenosis, with associated physical and psychosocial implications. She was not able to insert a tampon or have penetrative intercourse. After examination and shared decision-making, the patient underwent cystoscopy, vaginoscopy and posterior vaginoplasty with the goal to create a normal calibre vagina. Postoperative dilator use was recommended to prevent restenosis of the introitus. In clinic follow-up, the patient was observed to have a normal calibre vagina.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I)   in all stereoisomeric forms and their mixtures in any ratios where HB means maleic acid, to method of synthesis of compounds of the formula (I) that involves anionic exchange of compounds of the formula (II)   with maleic acid and/or maleates. Invention relates to also the pharmaceutical composition showing inhibitory effect on platelet aggregation or suppressing effect with respect of thrombosis. Therefore, compounds of the general formula (I) can be used as medicinal agents for prophylaxis of diseases associated with cardiovascular injuries. EFFECT: improved method of synthesis, valuable medicinal properties of compounds. 10 cl, 5 ex
The present invention relates to a method for producing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood; a method for differentiating the produced induced pluripotent stem cells into cardiovascular cells; and a use of the same. Endocardium-derived adult stem cells which are primary culture cells for producing the induced pluripotent stem cells of the present invention can be easily isolated and cultured only through a small quantity of peripheral blood, and have high proliferation power. Thus, the endocardium-derived adult stem cells can be stored without having a genetic mutation, and the number of cells which can be used for cell treatment can be rapidly ensured. Moreover, the endocardium-derived adult stem cells have stemness, so induced pluripotent stem cell production efficiency through transduction of four Yamanaka factors is high compared to conventionally used skin fibroblasts. Since the endocardium-derived adult stem cells are endocardium-derived and thus have eugenic memories of cardiovascular cells, produced induced pluripotent stem cells can be differentiated into cardiovascular cells such as endothelial cells, smooth muscle cells, and cardiac muscle cells at high efficiency. Accordingly, the cardiovascular cells differentiated from the induced pluripotent stem cells can be used in screening a library of a treating material for developing a specific cardiovascular disease treating agent and studying the mechanism of cardiovascular disorders. Moreover, cells are directly operated and proliferated, and are then re-fed to a patient to be widely used in various fields including a cell treating agent field.
The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
Vascular toxicities coincident with the use of bleomycin in combination with other antineoplastic agents have been reported. The events are clinically heterogeneous and may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (HUS), or cerebral arteritis. Various mechanisms have been proposed for these vascular complications. There are also reports of Raynaud's phenomenon occurring in patients treated with bleomycin in combination with vinblastine with or without cisplatin or, in a few cases, with bleomycin as a single agent. It is currently unknown if the cause of Raynaud's phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, hypomagnesemia, or a combination of any of these factors.

Fever, chills, and vomiting have been reported. Anorexia and weight loss have been reported and may persist long after termination of this medication. Pain at tumor site, phlebitis, and other local reactions have been reported.

Malaise has been reported.
Neonatal mortality within the first few days of life is a pressing issue in sub-Saharan Africa, including Ethiopia. Despite efforts to achieve the targets set by the Sustainable Development Goals, the rate of neonatal mortality in Ethiopia has increased from 29 to 33 deaths per 1000 live births. This study aimed to investigate and identify significant determinants of neonatal mortality within the first 72 h of life in Ethiopia. Utilizing data from the 2019 Ethiopia Demographic and Health Survey, we employed Generalized Poisson regression analysis following rigorous model fitness assessment. Our study encompassed 5527 weighted live-born neonates. Among women in their reproductive years, 3.1% (n = 174) experienced at least one very early neonatal death. Multiple births (Incidence Risk Ratio (IRR) = 3.48; CI = 1.76, 6.887) and birth order six or above (IRR = 2.23; CI = 1.008, 4.916) were associated with an increased risk of neonatal death within the first 72 h. Conversely, household size (IRR = 0.72; CI = 0.586, 0.885) and additional feeding practices (IRR = 0.33; CI = 0.188, 0.579) were found to mitigate the risk of very early neonatal mortality per mother in Ethiopia. Interventions targeting the identified risk factors and promoting protective factors can contribute to reducing very early neonatal mortality rates and improving the well-being of mothers and their newborns. Further research and implementation of evidence-based strategies are needed to address these challenges and ensure better neonatal outcomes in Ethiopia.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic to be excellently used in combination with an arbitrary cosmetic, and to provide a beauty regimen.  <P>SOLUTION: The cosmetic includes a nonwoven fabric with the impregnation of a liquid composition and a wet sheet is used in combination with the individually existing arbitrary cosmetic. It is preferable that the shape of the nonwoven fabric is a bag shape or a cylindrical shape. It is preferable that the wet sheet is used for soaking the cosmetic into skin after impregnating the cosmetic and is used for wiping off a cleansing cosmetic which is previously applied to the skin. The beauty regimen is performed by impregnating the wet sheet, which is composed of the nonwoven fabric with the impregnation of the liquid composition, with the individually existing arbitrary cosmetic, so as to massage the skin. The cleansing cosmetic which is previously applied to the skin is wiped off with the wet sheet which is composed of the nonwoven fabric with the impregnation of the liquid composition.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A therapeutic serum suitable for inclusion in a cosmetic preparation may be produced by stressing a co-culture including proliferative cells. The co-culture of cells may be obtained by first establishing a monolayer of cells on a surface. After a monolayer of first culture is established, a second culture comprising more resilient and/or aggressive cells may be over-seeded on the monolayer and established. Additional cultures comprising increasingly dominant cells may then be over-seeded and established until a monolayer having the desired population of cells is obtained. The monolayer is then stressed to obtain a serum by conditioning a collection medium. The obtained serum may be combined with a suitable cosmetic base to provide a cosmetic preparation.
FIELD: applied microbiology. SUBSTANCE: vaccinal strain A/47/Sydney/97/14 (H3N2), which is reassortant, is obtained by cross-breeding of epidemic virus A/Sydney/5/97/ (H3N2) with cold-adapted temperature-sensitive virus A/Leningrad/134/47/57 (H2N2), which is attenuation donor. Strain A/47/Sydney/97/14 (H3N2) actively multiplies in developing chicken embryos at optimal temperature 34 C. Strain is characterized by temperature sensitivity and cold adaptability. Reassortant inherits two genes from epidemic virus, which encode surface proteins (gemmagglutinin and neuraminidase). It also receives six genes encoding non-glycosylated proteins from attenuation donor. In addition, the strain does non induce immune response in babies during intranasal injection. Biological properties and low degree of immunoreactivity meet requirements for vaccine strains. EFFECT: enabled prophylactics of epidemic influenza provoked by specific antigenic virus species. 1 tbl
BACKGROUND: Chronic kidney disease (CKD) poses a significant health risk in contemporary society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, albeit associated with hyperkalemia risks. A novel selective mineralocorticoid receptor antagonist, finerenone, offers a promising, safer alternative for CKD therapy. This review comprehensively assesses the role and efficacy of finerenone in CKD treatment by analyzing clinical and animal studies. Emerging evidence consistently supports finerenone's ability to effectively slow the progression of CKD. By targeting the mineralocorticoid receptor, finerenone not only mitigates renal damage but also exhibits a favorable safety profile, minimizing hyperkalemia concerns.
CONCLUSION: Finerenone emerges as a valuable addition to CKD therapy, demonstrating potential benefits in delaying CKD progression while minimizing side effects. Nevertheless, further clinical trials are necessary to provide a comprehensive understanding of its safety and efficacy.
OBJECTIVE: Minimally invasive atlantoaxial surgery offers the benefits of reduced trauma and quicker recovery. Previous studies have focused on feasibility and technical aspects, but the lack of comprehensive safety information has limited its availability and widespread use. This study proposes to define the feasibility and range of surgical safety using the intersection of the greater occipital nerve and the inferior border of the inferior cephalic oblique as a reference point.
METHODS: Dissection was performed on 10 fresh cadavers to define the anatomical reference point as the intersection of the greater occipital nerve and the inferior border of the inferior cephalic oblique muscle. The study aimed to analyze the safety range of minimally invasive atlantoaxial fusion surgery by measuring the distance between the anatomical reference point and the transverse foramen of the axis, the distance between the anatomical reference point and the superior border of the posterior arch of the atlas, and the distance between the anatomical reference point and the spinal canal. Measurements were compared using Student's t test.
RESULTS: The point where the occipital greater nerve intersects with the inferior border of the inferior cephalic oblique muscle was defined as the anatomical marker for minimally invasive posterior atlantoaxial surgery. The distance between this anatomical marker and the transverse foramen of the axis was measured to be 9.32 ± 2.04 mm. Additionally, the distance to the superior border of the posterior arch of the atlas was found to be 21.29 ± 1.93 mm, and the distance to the spinal canal was measured to be 11.53 ± 2.18 mm. These measurement results can aid surgeons in protecting the vertebral artery and dura mater during minimally invasive posterior atlantoaxial surgery.
CONCLUSIONS: The intersection of the greater occipital nerve with the inferior border of the inferior cephalic oblique muscle is a safe and reliable anatomical landmark in minimally invasive posterior atlantoaxial surgery.
This invention relates to disease detection by imaging and treatment of virus infection. Previously, there was no way to use CEST MRI imaging to early detect and map the neurodegenerative diseases, multiple sclerosis disease, concussion, and traumatic brain injury. Also, previously, there was no way to use Computed Tomography (CT) imaging to early detect and map the neurodegenerative diseases. Embodiments of the present invention use a non-invasive CEST MRI imaging method is disclosed for early detection of diseases by using MRI or by using CT. The endogenous (MRI) contrast of the biological tissue can rely on the endogenous protons of the proteins and peptides as a source of the contrast, such as hydroxyl, amine, and amide protons, and thereby provide imaging and mapping for the early detection of the neurodegenerative diseases, multiple sclerosis disease, concussion, traumatic brain injury, and other diseases by using endogenous protons contrast via CEST MRI. Also, the exogenous agents can be used to produce MRI contrast, such as agents contain exchangeable protons and thereby provide imaging and mapping the inflammation in cancer and the expressed proteins in cancer cells for cancer detection. Also, using exogenous CT contrast agents for detection of amyloid beta, tau protein, alpha-synuclein protein, and aggregation proteins in neurodegenerative diseases and inflammation in many diseases such as neurodegenerative diseases, cancer and other inflammatory diseases Also, this invention relates to novel methods of treatment virus infection and enhance the immune system to produce antibodies against the viruses.
Background and Objectives: Surgical wound analgesia has been analyzed in many studies, but few have focused on its relationship with inflammatory markers. As such, we aimed to determine the influence of analgesic surgical wound infiltration in open colorectal surgery on the seric levels of pro- and anti-inflammatory markers and the associated efficacy in postoperative pain control. Materials and Methods: Forty patients who underwent open colorectal surgery were prospectively randomized: group 0, epidural analgesia; group 1, intravenous analgesia (control), group 2, preincision and prelaparoraphy infiltration; and, group 3, prelaparoraphy infiltration. Wound infiltration was performed with ropivacaine. We analyzed the levels of IL-6 and IL-10 cytokines before and 6 h after surgery and their correlation with pain scores. Results: The postoperative Il-6 levels were significantly lower in group 0 than in the control (p = 0.041). The postoperative Il-10 levels were significantly higher in group 3 (p = 0.029) than in the control. Six hours after the operation, the pain scores were significantly lower in all groups than in the control (p = 0.005, p = 0.022, and p = 0.017 for groups 0, 2, and 3, respectively). Pain scores were significantly correlated with Il-10 levels in group 2 (p = 0.047); in group 3, IL-10 levels directly correlated with those of Il-6 (p = 0.026). Conclusions: The analgetic effect of preincisional and prelaparoraphy analgetic infiltration was efficient. The analgetic infiltration of the surgical wound prior to closure stimulates both the inflammatory activator and regulator interleukins.
Patients in group A will be treated with the help of Instrument Assisted soft tissue mobilization GRASTON technique along with the conventional treatment. • Patient will be prone position with the foot over the edge of the table. Instrument will be applied from downward to upward direction with maximum of 10 - 15 strokes per session. These strokes will be applied in two sets of 10 strokes followed by stretches after each set. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week \& at the end of 4th week.